ASND Ascendis Pharma A/S Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
02:54
Aug 18
Aug 18
JPMorgan raises its target price on Ascendis Pharma to $300 from $295.
JPMorgan raises its target price on Ascendis Pharma to $300 from $295, indicating a bullish outlook on the stock.
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
11:58
Aug 17
Aug 17
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
MED
About ASND Analyst Coverage
Buzzberg tracks ASND (Ascendis Pharma A/S) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (20%). 5 total trade ideas tracked. Latest voices: FirstSquawk, seedy19tron.